HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jain, S. P. Articles by Collins, T. J. Search for Related Content PubMed PubMed Citation Articles by Jain, S. P. Articles by Collins, T. J.

CLINICAL STUDIES

Coronary stenting in cardiac allograft vasculopathy

^a Department of Cardiology, Ochsner Clinic, New Orleans, Louisiana, USA

Manuscript received March 6, 1998; revised manuscript received July 1, 1998, accepted July 24, 1998.

Address for correspondence: Dr. Stephen R. Ramee, Director of the Cardiac Catheterization Laboratory, Ochsner Clinic, 1514 Jefferson Highway, New Orleans, Louisiana 70121
sramee{at}aol.com

Objective. The purpose of this study was to evaluate acute angiographic success, in-hospital complications and long-term outcome after intracoronary stenting in patients with cardiac allograft vasculopathy.

Background. The application of conventional interventional modalities to treat discrete lesions in patients with cardiac allograft vasculopathy is associated with higher procedural morbidity, mortality and higher restenosis compared to atherosclerotic coronary artery disease. Elective coronary stenting has been shown to lower restenosis rates and improve long-term outcome in selected patients with native coronary artery disease; however, its safety and efficacy in reducing restenosis in patients with cardiac allograft vasculopathy is unknown.

Methods. Ten patients with 19 discrete lesions in a major coronary artery without diffuse distal disease underwent intracoronary stenting using Palmaz–Schatz stents. The average stent size was 3.4 mm, and the stent/artery ratio was 0.99 ± 0.07. Eight of ten (80%) patients received antiplatelet therapy (aspirin plus ticlopidine) only.

Results. Procedural success was 100% with no in-hospital stent thrombosis, Q-wave myocardial infarction or death. Minimal luminal diameter increased from 0.83 ± 0.38 mm to 3.23 ± 0.49 mm after stenting. Diameter stenosis decreased from 74.91 ± 11.52% to 5.90 ± 4.09% after stenting. Follow-up angiography was performed in 8 of 10 (80%) patients and 16 of 19 (84%) lesions. Target lesion revascularization was required in 2 of 10 (20%) patients and 3 of 16 (19%) lesions. Allograft survival was 7 of 10 (70%) at the end of 22 ± 11 months follow-up.

Conclusions. Intracoronary stenting can be performed safely with excellent angiographic success in selected patients with cardiac allograft vasculopathy. The restenosis rate appears to be low despite the aggressive nature of the disease. A multicenter study with a larger number of patients is required to assess its efficacy in reducing restenosis and improving allograft survival.

Abbreviations and Acronyms   CAV = cardiac allograft vasculopathy   CK = creatinine kinase   HMG Co-A = hydroxymethylglutaryl coenzyme A   MLD = minimal luminal diameter

This article has been cited by other articles:

				M. Jonas, J. C. Fang, J. C. Wang, S. Giri, D. Elian, Y. Har-Zahav, H. Ly, P. A. Seifert, J. J. Popma, and C. Rogers In-Stent Restenosis and Remote Coronary Lesion Progression Are Coupled in Cardiac Transplant Vasculopathy But Not in Native Coronary Artery Disease J. Am. Coll. Cardiol., August 1, 2006; 48(3): 453 - 461. [Abstract] [Full Text] [PDF]

				R. L. Benza, G. J. Zoghbi, J. Tallaj, R. Brown, J. K. Kirklin, M. Hubbard, B. Rayburn, B. Foley, D. C. McGiffin, L. J. Pinderski, et al. Palliation of allograft vasculopathy with transluminal angioplasty: A decade of experience J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1973 - 1981. [Abstract] [Full Text] [PDF]